{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6","upperLimit":"27","value":"14.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"CRi: ≤ 5% blasts by morphology in BM; ANC ≥ 1000/µL and Plt \\< 100000/µL or ANC \\< 1000/µL and Plt ≥ 100000/µL in PB; CNS EMD of CNS-1 (no detectable leukemia in CSF); Non-CNS EMD: if baseline EMD present (images must show CR), if no baseline EMD (then images not required), but if performed should show negative PET baseline, baseline lesions must show CR as disappearance of measurable and nonmeasurable nodal lesions (Nodal masses \\> 1.5 cm in GTD at baseline must have regressed to ≤ l.5 cm GTD, nodes that were 1.1 to 1.5 cm \\[long axis\\] and \\> 1.0 cm \\[short axis\\] must have decreased to 1.0 cm in their short axis, spleen and/or liver must be normal size, if tested) and no new lesions. Percentage of participants with CRi was reported. 95% CI was calculated by Clopper-Pearson method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with r/r B-ALL received conditioning chemotherapy (fludarabine 25 mg/m\\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\\^2 IV over 60 minutes on Day -2) followed by a single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered IV at a target dose of 1 x 10\\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \\> 100 kg, a maximum flat dose of 1 x 10\\^8 anti-CD19 CAR T cells/kg of body weight was administered.","id":"OG000","title":"Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg"}],"paramType":"NUMBER","populationDescription":"Participants in mITT Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"First infusion date of brexucabtagene autoleucel (Phase 2) up to 3.7 years","title":"Phase 2: Complete Remission With Incomplete Hematologic Recovery (CRi) Rate Per Independent Review","type":"SECONDARY","unitOfMeasure":"percentage of participants"}